Recognizing that significant advances were taking place in the understanding of B-cell tumor biology, TG was founded in 2012 with one goal in mind… to leverage these significant advances in order to create the best possible treatment options for patients with B-cell diseases. Back then, we were a small group of people with big dreams and a personal drive and commitment to challenge the status quo of drug development. Over the years our company has evolved, and our team has grown, but we remain true to our original goal!
From the beginning, we believed the cure or best solution for patients with these diseases did not lie in the development of a single drug but would only be found through the development of combinations of drugs. And thus our unique strategy was born…to leverage these biological advances in order to develop combinations of novel targeted and immune therapies that could provide better outcomes without the need for toxic chemotherapy.
We’ve dedicated ourselves to this simple concept and to the study of B-cells and B-cell diseases. To achieve our goal, we search the globe looking for medicines in early research that we believe could be combined to create better treatment options for patients. Each medicine is just a piece of the puzzle, none the solution on its own.
The team’s dedication and hard work over the last 8 years have brought us to where we are today. We currently have 5 unique medicines under development, being studied in 40 clinical trials with 4 potential approvals in the 2020-2021 timeframe for patients with CLL, MZL, FL, and MS. Our 176 employees located in our 4 offices have a lot to be proud, especially the small group that originally formed TG who are all still with us today!